159 related articles for article (PubMed ID: 23791685)
1. Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring.
Externbrink A; Clark MR; Friend DR; Klein S
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):966-73. PubMed ID: 23791685
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of accelerated drug release testing methods for a matrix-type intravaginal ring.
Externbrink A; Eggenreich K; Eder S; Mohr S; Nickisch K; Klein S
Eur J Pharm Biopharm; 2017 Jan; 110():1-12. PubMed ID: 27793758
[TBL] [Abstract][Full Text] [Related]
3. In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring.
van Laarhoven JA; Kruft MA; Vromans H
Int J Pharm; 2002 Jan; 232(1-2):163-73. PubMed ID: 11790500
[TBL] [Abstract][Full Text] [Related]
4. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.
Woolfson AD; Malcolm RK; Morrow RJ; Toner CF; McCullagh SD
Int J Pharm; 2006 Nov; 325(1-2):82-9. PubMed ID: 16884869
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a Molding Procedure to Facilitate Formulation Development for Co-extrudates.
Eder S; Beretta M; Witschnigg A; Koutsamanis I; Eggenreich K; Khinast JG; Koscher G; Paudel A; Nickisch K; Friedrich M; Froehlich E; Roblegg E
AAPS PharmSciTech; 2017 Nov; 18(8):2971-2976. PubMed ID: 28462464
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery.
Reza MS; Quadir MA; Haider SS
J Pharm Pharm Sci; 2003; 6(2):282-91. PubMed ID: 12935440
[TBL] [Abstract][Full Text] [Related]
7. The contraceptive vaginal ring.
Edwardson J; Jamshidi R
Semin Reprod Med; 2010 Mar; 28(2):133-9. PubMed ID: 20352563
[TBL] [Abstract][Full Text] [Related]
8. Elevated temperature accelerated release testing of PLGA microspheres.
Zolnik BS; Leary PE; Burgess DJ
J Control Release; 2006 May; 112(3):293-300. PubMed ID: 16644055
[TBL] [Abstract][Full Text] [Related]
9. The contraceptive vaginal ring, NuvaRing(®), a decade after its introduction.
Roumen FJ; Mishell DR
Eur J Contracept Reprod Health Care; 2012 Dec; 17(6):415-27. PubMed ID: 23113828
[TBL] [Abstract][Full Text] [Related]
10. Optimised process and formulation conditions for extended release dry polymer powder-coated pellets.
Terebesi I; Bodmeier R
Eur J Pharm Biopharm; 2010 May; 75(1):63-70. PubMed ID: 20079833
[TBL] [Abstract][Full Text] [Related]
11. Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal Consta.
Rawat A; Stippler E; Shah VP; Burgess DJ
Int J Pharm; 2011 Nov; 420(2):198-205. PubMed ID: 21889583
[TBL] [Abstract][Full Text] [Related]
12. Drug release behaviour from methyl methacrylate-starch matrix tablets: effect of polymer moisture content.
Bravo-Osuna I; Ferrero C; Jiménez-Castellanos MR
Eur J Pharm Biopharm; 2008 May; 69(1):285-93. PubMed ID: 17997292
[TBL] [Abstract][Full Text] [Related]
13. Effect of supersaturation and crystallization phenomena on the release properties of a controlled release device based on EVA copolymer.
van Laarhoven JA; Kruft MA; Vromans H
J Control Release; 2002 Aug; 82(2-3):309-17. PubMed ID: 12175745
[TBL] [Abstract][Full Text] [Related]
14. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing.
Bruni V; Pontello V; Luisi S; Petraglia F
Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):65-71. PubMed ID: 18358586
[TBL] [Abstract][Full Text] [Related]
15. The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage.
Verhoeven CH; Dieben TO
Contraception; 2004 Mar; 69(3):197-9. PubMed ID: 14969666
[TBL] [Abstract][Full Text] [Related]
16. The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication.
Verhoeven CH; van den Heuvel MW; Mulders TM; Dieben TO
Contraception; 2004 Feb; 69(2):129-32. PubMed ID: 14759617
[TBL] [Abstract][Full Text] [Related]
17. Vaginal drug delivery: strategies and concerns in polymeric nanoparticle development.
Wong TW; Dhanawat M; Rathbone MJ
Expert Opin Drug Deliv; 2014 Sep; 11(9):1419-34. PubMed ID: 24960192
[TBL] [Abstract][Full Text] [Related]
18. Differential scanning calorimetry and surface morphology studies on coated pellets using aqueous dispersions.
Nisar-ur-Rahman ; K H Y; Jia Woei W; Khan NA
Pak J Pharm Sci; 2005 Apr; 18(2):19-23. PubMed ID: 16431393
[TBL] [Abstract][Full Text] [Related]
19. Controlled release polymeric ocular delivery of acyclovir.
Deshpande PB; Dandagi P; Udupa N; Gopal SV; Jain SS; Vasanth SG
Pharm Dev Technol; 2010; 15(4):369-78. PubMed ID: 19772377
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of the NuvaRing® Applicator in healthy females: a multicenter, open-label, randomized, 2-period crossover study.
Feldman R; Frenkl TL; Yacik C; Wang Y; Fox MC
Contraception; 2016 Oct; 94(4):362-5. PubMed ID: 27207028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
